NCT06984146 Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
| NCT ID | NCT06984146 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | National Medical Research Radiological Centre of the Ministry of Health of Russia |
| Condition | Hodgkin Lymphoma, Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2025-04-15 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 54 participants in total. It began in 2025-04-15 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
Eligibility Criteria
Inclusion Criteria: 1. Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma 2. No past history of autoimmune disease 3. Age \> 18 years 4. Ejection fraction \> 50% 5. ECOG 0-4 Exclusion Criteria: 1. Organ failure (e.g. creatinine \> 2x ULN; ALT or AST \> 5x ULN; bilirubin \> 2x ULN; hemodynamic instability; respiratory failure \> Grade 1) 2. Uncontrolled infection 3. Pregnancy 4. Inability to sign informed consent
Contact & Investigator
Andrey Kaprin
STUDY CHAIR
FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation
Frequently Asked Questions
Who can join the NCT06984146 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hodgkin Lymphoma, Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06984146 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06984146 currently recruiting?
Yes, NCT06984146 is actively recruiting participants. Contact the research team at mobilakhmedov@gmail.com for enrollment information.
Where is the NCT06984146 trial being conducted?
This trial is being conducted at Moscow, Russia.
Who is sponsoring the NCT06984146 clinical trial?
NCT06984146 is sponsored by National Medical Research Radiological Centre of the Ministry of Health of Russia. The principal investigator is Andrey Kaprin at FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation. The trial plans to enroll 54 participants.